CTNPT016: Herpesvirus shedding among HIV inpatients

In 2005, a clinical trial using HF10 to treat pancreatic cancer was initiated. Adeno-associated virus (AAV) vectors are currently among the most frequently used viral vectors for gene therapy. In 2005, a clinical trial using HF10 to treat pancreatic cancer was initiated. Among 163 patients with less advanced melanoma, people treated with T-VEC survived an average of 41 months compared to 21.5 months for 66 patients treated with other therapy. Co-infection with herpes viruses such as herpes simplex virus type 2 (HSV-2) and cytomegalovirus (CMV) is common for adults living with HIV. In this review, we summarize the history and current status of preclinical and clinical studies of oncolytic virus therapy using HSV-1. Incomplete understanding of the nature of infections, lack of knowledge about the immune response, and an inability to tinker with either infections or host hampered progress.

Cytomegalovirus viremia correlated with clinical syndromes and was more frequent in recipients of antithymocyte globulin. Both injected and uninjected regional and distant disease demonstrated response including clearly documented responses at uninjected visceral sites. However, the virus may be the cause of serious diseases, particularly in immunocompromised individuals. Recurrent, incurable viral infection characterized by painful vesicular eruption of the skin and mucosa of the genitals. Ninety-two percent of the responses had been maintained for 7 to 31 months. Another fact that physicians didn’t realize is that HSV-1 is best kept at bay using not just antiviral medications, but through a combination of antivirals and other drug types. Clinical studies were performed under Investigational New Drug application 20,496, and the results were published in several papers in the mid-1980s (Young, Schneider, Leyland-Jones, Armstrong, Tan, Lopez, Watanabe, Fox, and Philips, 1983; Leyland-Jones, Donnelly, Groshen, Myskowski, Donner, Fanucchi, and Fox, 1986) by the MSKC Antiviral Working Group.


Eighty-two percent of the women had recurrent genital herpes; 12% had first episode, nonprimary genital herpes; and 6% had first episode, primary genital herpes. Patients whose CFS symptoms are not spontaneously improving and have plateau for at least 6 months. Efforts to develop KSHV vaccines have been more limited. Patients continued on the medication for two years unless they had a sustained progression or repeated exacerbations. Duration of cold sore lesions, severity of signs and symptoms, and frequency of adverse effects. Disseminated CMV disease is rare (occuring in less than 5 percent of those with CMV disease), but is ominous when it occurs since it is usually fatal (Chazouilleres and Wright, in press). The virus is similar to other forms of herpes and spreads through contact.

Previously, it was shown that disruption of the U(L)41 gene can increase the efficacy of dl5-29 as a vaccine against HSV-2. Further open trial work with these 2 viruses appears necessary to improve dose regimens or to employ combination therapy or study new derivatives or agents before controlled trials are warranted. Chimerix and the University of Oxford are in the process of finalizing a definitive agreement for supplying brincidofovir for the planned clinical trial. What is needed now are studies combining sequential interventions so that patients who fail, for example, prophylaxis with one drug can be entered directly into trials of suppression and then into pre-emptive therapy, each with different antiviral agents. In these patients, immunosuppressive medications could be adjusted, or antiviral medications administered. In an international trial, 945 patients with advanced melanoma were treated using the drugs ipilimumab and nivolumab. The effectiveness of OVs has been demonstrated in many preclinical studies and recently in humans, with US Food and Drug Administration approval of the oncolytic herpesvirus talimogene laherparepvec in advanced melanoma, a major breakthrough for the field.

HHV6 reactivation was less frequent in patients who received reduced-intensity conditioning (P = .028). Human herpesvirus 8 (HHV-8) replication is critical in the induction and maintenance of Kaposi sarcoma, primary effusion lymphoma and some cases of Castleman disease. From a diagnostic point of view, HHV-8 currently appears as a useful tool for distinguishing KS from its mimics. This commentary is based solely on the material available in the aforementioned sources; the committee did not review the individual patient records at MSKC. Population Age: Infants and toddlers, Under 18 Gender: Male, Female Trial protocol: DE (Completed) EE (Completed) Trial results: (No results available) EudraCT Number: 2004-002676-41 Sponsor Protocol Number: 100388,103494,104105,104106 Start Date*: 2005-05-23 Sponsor Name:GlaxoSmithKline Biologicals Full Title: Blinded, randomised, controlled, multicenter study to evaluate the clinical efficacy against varicella disease of GlaxoSmithKline Biologicals’ live attenuated varicella vaccine (Varilrix) given on … Medical condition: Subjects with a clinical diagnosis of Herpes Simplex Labialis on the perioral area. The investigators will conduct a single-center, prospective, randomized, placebo-controlled, double-blind pilot study of anti-herpesvirus therapy in patients with idiopathic pulmonary fibrosis (IPF).

EudraCT Number: 2004-002676-41 Sponsor Protocol Number: 100388,103494,104105,104106 Start Date*: 2005-05-23 Sponsor Name:GlaxoSmithKline Biologicals Full Title: Blinded, randomised, controlled, multicenter study to evaluate the clinical efficacy against varicella disease of GlaxoSmithKline Biologicals’ live attenuated varicella vaccine (Varilrix) given on …